Genentech's Tecentriq & Lurbinectedin Show Positive Results In Phase III Trial For ES-SCLC
3/6 03:40
(RTTNews) - Genentech, a member of the Roche Group (RHHBY), announced positive results from the Phase III IMforte study of Tecentriq (atezolizumab) in combination with lurbinectedin (Zepzelca) as a first-line maintenance treatment for people with extensive-stage small cell lung c...